The mitogen‐activated protein kinase (MAPK) signaling pathway plays a significant role in
mediating cellular physiological activities, such as proliferation, differentiation, apoptosis …

Activating BRAF mutations, leading to constitutive activation of the MAPK signaling pathway,
are common in a variety of human cancers. Several small molecule BRAF inhibitors have …

Selective BRAF inhibitors have now been established as a standard of care option for
patients diagnosed with metastatic melanoma whose tumors carry a BRAF mutation. Their …

Introduction: After its identification as an oncogene in 2002, mutant BRAF has become the
target of a number of drug discovery programmes, primarily aimed at the treatment of late …

Background Mutations in BRAF were first reported in 2002. Since that time, the molecular
basis for oncogenic signaling has been elucidated in multiple malignancies. The …

With the identification of activating mutations in BRAF across a wide variety of malignancies,
substantial effort was placed in designing safe and effective therapeutic strategies to target …

Opinion statement Melanoma is caused by a variety of somatic mutations, and among these
mutations, BRAF mutation occurs most frequently and has routinely been evaluated as a …

Opinion Statement BRAF mutations are present in up to 8% of human cancers, and
comprise a viable therapeutic target in many patients harboring these mutations. Specific …

The successful translation of therapies targeting signal‐transduction pathways that are
activated by oncogenes has provided a model for molecularly targeted therapy, and the …

Understanding the role of mitogen-activated protein kinase (MAPK) pathway-activating
mutations in the development and progression of melanoma and their possible use as …